Elevation Oncology, Inc. (ELEV)
NASDAQ: ELEV · Real-Time Price · USD
0.3730
+0.0010 (0.27%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Company Description

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.

It’s lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload that is in Phase 1 clinical trial as a monotherapy and in combinations with dostarlimab, a PD-1 inhibitor, and ramucirumab, a VEGFR2 inhibitor, in patients with advanced, unresectable, or metastatic gastric/gastroesophageal junction solid tumors.

The company is also developing EO-1022, an ADC containing seribantumab, a fully human immunoglobulin G2 (IgG2) anti-HER3 mAb, and an MMAE payload, with glycan site-specific conjugation for the treatment of patients with HER3-expressing solid tumors, including breast cancer, non-small cell lung cancer, and other solid tumors.

It has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021 for the treatment of cancer.

The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020.

The company was incorporated in 2019 and is based in Boston, Massachusetts.

Elevation Oncology, Inc.
Elevation Oncology logo
Country United States
Founded 2019
IPO Date Jun 25, 2021
Industry Biotechnology
Sector Healthcare
Employees 34
CEO Joseph Ferra

Contact Details

Address:
101 Federal Street, Suite 1900
Boston, Massachusetts 02110
United States
Phone 716 371 1125
Website elevationoncology.com

Stock Details

Ticker Symbol ELEV
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001783032
CUSIP Number 28623U101
ISIN Number US28623U1016
Employer ID 84-1771427
SIC Code 2836

Key Executives

Name Position
Joseph J. Ferra Jr. Chief Executive Officer, President and Director
Tammy Furlong CPA, P.M.P. Chief Financial Officer and Secretary
Robert C. Yang Senior Vice President and General Counsel

Latest SEC Filings

Date Type Title
Apr 24, 2025 ARS Filing
Apr 24, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2025 DEF 14A Other definitive proxy statements
Apr 16, 2025 SCHEDULE 13D Filing
Apr 11, 2025 PRE 14A Other preliminary proxy statements
Apr 4, 2025 8-K Current Report
Apr 1, 2025 8-K Current Report
Mar 26, 2025 SCHEDULE 13G Filing
Mar 20, 2025 8-K Current Report
Mar 19, 2025 8-K Current Report